What question did this study set out to answer?

Evaluate real-world clinical quality and cost outcomes associated with an insurer-implemented clinical pathway program for breast cancer chemotherapy.

October 15, 2018Journal of Oncology Practice

Results From a Health Insurer's Clinical Pathway Program in Breast Cancer

View Full Paper

Ask AI

Bookmark

Authors

SGSantosh GautamJohnson & Johnson (Israel)GSGosia SylwestrzakUniversity of Kentucky HealthCare JBJohn BarronCleveland Clinic

Discussion

Member takes

Implication

Propensity-matched cohort study demonstrates lower healthcare costs without compromised quality in breast cancer, indicating the high value of clinical pathway adherence.

Key Points

Evaluate real-world clinical quality and cost outcomes associated with an insurer-implemented clinical pathway program for breast cancer chemotherapy.
Analyzed claims and clinical data from Anthem's Cancer Care Quality Program for patients initiating chemotherapy between January 2015 and October 2016.
Applied 1:1 propensity score matching based on demographic and clinical factors to compare on-pathway and off-pathway treatment (N = 959 per cohort).
Assessed 6-month quality-of-care outcomes (hospitalizations, emergency visits, supportive drug use) and overall care costs.
Rates of hospitalization and emergency department visits were similar between both cohorts over the 6-month follow-up period.
Granulocyte colony-stimulating factor use was significantly lower in the on-pathway cohort than the off-pathway cohort (72.5% vs 82.8%; OR, 0.55; P ≤ .0001).
Average 6-month cost of care was significantly reduced in the on-pathway cohort, with a mean difference of -$16,176 (95% CI, -$24,291 to -$8,061; P ≤ .0001).

Cite This Study

Gautam et al. (2018) studied this question.

synapsesocial.com/papers/6a85c6dc47743a7c6cd4eb4c https://doi.org/10.1200/jop.18.00157

View Full Paper

Ask AI

Bookmark

Implication

Propensity-matched cohort study demonstrates lower healthcare costs without compromised quality in breast cancer, indicating the high value of clinical pathway adherence.

Results From a Health Insurer's Clinical Pathway Program in Breast Cancer

Discussion

Member takes

Implication

Key Points

Cite This Study

Results From a Health Insurer's Clinical Pathway Program in Breast Cancer

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider